An Investigator-Initiated Open-Label, Multiple-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy for 2 Leber's Congenital Amaurosis With RPE65 Mutation (LCA2)
Latest Information Update: 06 Oct 2023
At a glance
- Drugs HG-004 (Primary)
- Indications Leber congenital amaurosis; Retinal dystrophies
- Focus Adverse reactions
Most Recent Events
- 02 Feb 2023 New trial record
- 27 Jan 2023 Results presented in a Huidagene Therapeutics Media Release.